Bayer
Business & Industry
- Bayer and NextRNA Therapeutics enter strategic collaboration to develop small molecules targeting long non-coding RNAs (lncRNAs) in oncology
- Pfizer launches PfizerForAll™, a digital platform that helps simplify access to healthcare
- Pfizer and BioNTech provide update on mRNA-based combination vaccine program against influenza and COVID-19 in individuals 18-64 years of age
- Pfizer announces top-line results of ABRYSVO® for RSV in immunocompromised adults
- Novartis receives FDA accelerated approval for Fabhalta® (iptacopan)
Research & Development
- Immune cells prevent lung healing after viral infection
- Newly discovered antibody protects against all COVID-19 variants
- New pharmaceutically active substances from billions of newly combined molecules
- A discovery to set your heart a-knocking
- Common salt activates anti-tumor cells
- Game-changing needle-free COVID-19 intranasal vaccine
- Deadly sea snail toxin could be key to making better medicines
Conferences & Events
- New insights into T and B cells offer hope for autoimmune disease sufferers
- SAE Media Group proudly presents the 4th Annual AI in Drug Discovery Conference
- SAE Media Group's 6th annual 3D Cell Culture Conference
- CPHI Frankfurt returns to pre-pandemic strength as pharma industry booms again
- 14th Annual RNA Therapeutics: Investigating the next generation of genetic medicine through RNA based therapies
- CPHI Excellence in Pharma Award Winners 2022
- CPHI Frankfurt Report predicts huge funding overhang to drive contract services growth
Regulatory Affairs
- FDA approves first nasal spray for treatment of anaphylaxis
- FDA approves nonsteroidal treatment for Duchenne muscular dystrophy
- FDA approves first gene therapies to treat patients with sickle cell disease
- FDA approves first therapy for rare type of non-cancerous tumors
- First electronic product information (ePI) published for selected human medicines